Rheumatoid arthritis: proposal for the use of anti-microbial therapy in early cases

Alan Ebringer1, Taha Rashid, Clyde Wilson

  • 1Division of Life Sciences, Infection and Immunity Group, King's College London, UK. alan.ebringer@kcl.ac.uk

Insights

Rheumatoid arthritis (RA) may stem from Proteus urinary tract infections. Targeting this bacteria with antibiotics or cranberry may aid RA management alongside standard treatments.

Area of Science:

  • Immunology
  • Microbiology
  • Rheumatology

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease disproportionately affecting women.
  • RA pathogenesis is linked to HLA-DR molecules with specific
  • shared epitope
  • amino acid sequences (EQK/RRAA).
  • Proteus mirabilis exhibits molecular mimicry to the
  • shared epitope
  • and hyaline cartilage collagen.

Purpose of the Study:

  • To investigate the hypothesis that recurrent Proteus upper urinary tract infections contribute to rheumatoid arthritis development.
  • To explore potential adjunctive therapies for RA management targeting Proteus infections.

Main Methods:

  • Review of existing studies reporting elevated antibodies to P. mirabilis in RA patients (1375 patients across 14 countries).
  • Analysis of P. mirabilis isolation from RA patient urine cultures.
  • Evaluation of anti-Proteus measures for potential RA management.

Main Results:

  • Elevated antibodies to P. mirabilis were found in a significant number of RA patients globally.
  • P. mirabilis was isolated from urine cultures of RA patients.
  • Anti-Proteus measures like antibiotics, hydration, and cranberry extracts show efficacy in urinary tract infection treatment.

Conclusions:

  • Recurrent Proteus upper urinary tract infections are a plausible etiological factor in rheumatoid arthritis.
  • Anti-Proteus strategies could serve as supplementary treatments for RA.
  • Further prospective studies are warranted to evaluate anti-Proteus measures in RA management.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Microbiota Modulation by Antibiotics01:21

Microbiota Modulation by Antibiotics

Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...